TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Nanjing Natinefy Pharmatech
US Patent
Nanjing Natinefy Pharmatech
US Patent
Affinity DataIC50: 0.390nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
Affinity DataIC50: 2.07nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
Affinity DataIC50: 5.70nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
Affinity DataIC50: 7.20nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
Affinity DataIC50: 7.40nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
Affinity DataIC50: 7.90nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Nanjing Natinefy Pharmatech
US Patent
Nanjing Natinefy Pharmatech
US Patent
Affinity DataIC50: 8.5nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
Affinity DataIC50: 9nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
Affinity DataIC50: 9.40nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
Affinity DataIC50: 9.5nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Nanjing Natinefy Pharmatech
US Patent
Nanjing Natinefy Pharmatech
US Patent
Affinity DataIC50: 10.2nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
Affinity DataIC50: 12.1nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
Affinity DataIC50: 12.7nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
Affinity DataIC50: 13.3nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
Affinity DataIC50: 14.3nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
Affinity DataIC50: 14.4nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
Affinity DataIC50: 15.6nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
Affinity DataIC50: 16.8nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
Affinity DataIC50: 19.4nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
Affinity DataIC50: 20.1nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
Affinity DataIC50: 22.4nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Nanjing Natinefy Pharmatech
US Patent
Nanjing Natinefy Pharmatech
US Patent
Affinity DataIC50: 28nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Nanjing Natinefy Pharmatech
US Patent
Nanjing Natinefy Pharmatech
US Patent
Affinity DataIC50: 28.4nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Nanjing Natinefy Pharmatech
US Patent
Nanjing Natinefy Pharmatech
US Patent
Affinity DataIC50: 29.5nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Nanjing Natinefy Pharmatech
US Patent
Nanjing Natinefy Pharmatech
US Patent
Affinity DataIC50: 31.2nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Nanjing Natinefy Pharmatech
US Patent
Nanjing Natinefy Pharmatech
US Patent
Affinity DataIC50: 36.4nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
Affinity DataIC50: 40nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
Affinity DataIC50: 40.3nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Nanjing Natinefy Pharmatech
US Patent
Nanjing Natinefy Pharmatech
US Patent
Affinity DataIC50: 47.1nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Nanjing Natinefy Pharmatech
US Patent
Nanjing Natinefy Pharmatech
US Patent
Affinity DataIC50: 48.9nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Nanjing Natinefy Pharmatech
US Patent
Nanjing Natinefy Pharmatech
US Patent
Affinity DataIC50: 60nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
Affinity DataIC50: 68.3nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Nanjing Natinefy Pharmatech
US Patent
Nanjing Natinefy Pharmatech
US Patent
Affinity DataIC50: 125nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
Affinity DataIC50: 143nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Nanjing Natinefy Pharmatech
US Patent
Nanjing Natinefy Pharmatech
US Patent
Affinity DataIC50: 182nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Nanjing Natinefy Pharmatech
US Patent
Nanjing Natinefy Pharmatech
US Patent
Affinity DataIC50: >5.00E+3nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Nanjing Natinefy Pharmatech
US Patent
Nanjing Natinefy Pharmatech
US Patent
Affinity DataIC50: >5.00E+3nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Nanjing Natinefy Pharmatech
US Patent
Nanjing Natinefy Pharmatech
US Patent
Affinity DataIC50: >5.00E+3nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Nanjing Natinefy Pharmatech
US Patent
Nanjing Natinefy Pharmatech
US Patent
Affinity DataIC50: >5.00E+3nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Nanjing Natinefy Pharmatech
US Patent
Nanjing Natinefy Pharmatech
US Patent
Affinity DataIC50: >5.00E+3nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Nanjing Natinefy Pharmatech
US Patent
Nanjing Natinefy Pharmatech
US Patent
Affinity DataIC50: >5.00E+3nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Nanjing Natinefy Pharmatech
US Patent
Nanjing Natinefy Pharmatech
US Patent
Affinity DataIC50: >5.00E+3nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Nanjing Natinefy Pharmatech
US Patent
Nanjing Natinefy Pharmatech
US Patent
Affinity DataIC50: >5.00E+3nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Nanjing Natinefy Pharmatech
US Patent
Nanjing Natinefy Pharmatech
US Patent
Affinity DataIC50: >5.00E+3nMAssay Description:A study on inhibition of protein kinases activity at in vitro biochemical levelMaterial and method: kinases such as c-Met, VEGFR-2, Axl and RET, obta...More data for this Ligand-Target Pair